An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy-Reference-Cited by-同舟云学术

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy

Published:2009-05 Issue:2 Volume:64 Page:199-206
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Tiseo Marcello,Gridelli Cesare,Cascinu Stefano,Crinò Lucio,Piantedosi Franco Vito,Grossi Francesco,Brandes Alba A.,Labianca Roberto,Siena Salvatore,Amoroso Domenico,Belvedere Ornella,Valentino Brunello,Bearz Alessandra,Venturino Paola,Ardizzoni Andrea

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference16 articles.

1. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer;Giaccone;J Clin Oncol,2005

2. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen;Johnson;Clin Cancer Res,2005

3. Determinants of tumour response and survival with erlotinib in patients with non-small-cell lung cancer;Perez-Soler;J Clin Oncol,2004

4. Erlotinib for front-line treatment of advanced non-small cell lung cancer: a phase II study;Giaccone;Clin Cancer Res,2006

5. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data;Lung Cancer;2018-12

2. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice;Supportive Care in Cancer;2016-10-07

3. Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC);Lung Cancer;2014-02

4. Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study);European Journal of Cancer Care;2013-10-24

5. Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Non–Small-Cell Lung Cancer;Clinical Lung Cancer;2013-07